CClinicalTrials.gg
TerminatedNCT03867006CARBOPTIMUSUpdated Apr 18, 2023

Optimization of the Preservation of Muscle Mass and / or Its Recovery by a Protein-energy Chrononutrition Approach Dissociated From Meals

An interventional study of Protein and Protein and Carbohydrate in Undernutrition, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Terminated at 3 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Prevention

Why this study was terminated
Stop funding by Regional Council of Auvergne-Rhône-Alpes, France
Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Muscle wasting has a multifactorial origin, including decreased physical activity, malnutrition, loss of post-incident muscle recovery abilities, and decreased ability to regenerate muscle. Among the strategies tested to improve the production of proteins and thus muscle is the supplementation of whey proteins. However this strategy does not seem sufficient and optimal to avoid muscle wasting and it must be complemented by a complementary action.

Muscle protein degradation also occurs during the nocturnal fasting periods to provide amino acids for energy purposes and to produce glucose, essential for vital organs. The preservation of the benefit of whey intake during meals could therefore be optimized by reducing the use of muscle proteins for energy purposes during the night.

Read the detailed description

In this study, three arms will be studied for 3 months: 1 control group, 1 group with whey supplementation at lunch, and 1 group with whey supplementation at lunch and an energy bolus before bedtime. Actions include weight and body composition monitoring, nutritional status and muscle function, as well as mechanistic.

02

Conditions studied

  • Undernutrition

Browse trials for

Keywords

  • Malnutrition
  • Undernutrition
  • Elderly
  • Protein
  • Carbohydrate
03

In context

Malnutrition

1,587 studies on the registry are indexed under Malnutrition; 237 are open to participants now.

This study's enrollment of 6 is below the median of 90 across 1,134 interventional studies indexed under Malnutrition.

Browse Malnutrition studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 578 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Resident on the Accommodation Establishments for Dependent Elderly Persons on the Mutuality of Loire, France
  • Risk of undernutrition or moderate undernutrition with one of the following criteria :

    • Either 5-10% of weight loss in 1 month or 10-15% in 6 months.
    • Or Body Mass Index (BMI) between 16 and 21
    • Or Albumin levels between 30 and 35 g/L
    • Or global Mini Nutritional Assessment (MNA) test between 17 and 23.5
    • Or Short Emergency Geriatric Assessment (SEGA) Score >8

Exclusion criteria

Exclusion Criteria:

  • Sub-acute pathology (flu, gastroenteritis, bacterial infections ...) or trauma (fracture, surgery ...) in the 30 days prior to inclusion.
  • Hepatocellular insufficiency
  • Heart failure with decompensation
  • Severe dementia,
  • Insulin-treated diabetes
  • Renal insufficiency (clearance \<30 ml / min)
  • Long-term cortico-therapy
  • Cancer undergoing chemotherapy treatment or/and radiotherapy
  • Gastrointestinal pathology,
  • Diet incompatible with the nutritional protocol (intolerance to milk or lactose, vegetarians, vegans, ...)
  • Motor disability leading to the impossibility of doing muscle function tests.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • No intervention
    control group

    Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).

  • Experimental
    protein group

    Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.

    Dietary Supplement: Protein

  • Experimental
    protein and carbohydrates group

    Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.

    Dietary Supplement: Protein and Carbohydrate

Interventions

  • Dietary supplementProtein

    In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.

  • Dietary supplementProtein and Carbohydrate

    In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.

06

What researchers measure

Primary outcomes

  1. Appendicular lean body mass (gramme)

    Comparison appendicular lean body mass between the day of inclusion and 90 days after. It is measuring by Dual Energy X-ray Absorptiometry (DEXA).

    Time frame: Days 0 and 90

Secondary outcomes

  1. total body composition

    Correlation between Dual Energy X-ray Absorptiometry (DEXA) results and bioelectrical impedance analysis results to determine total body composition.

    Time frame: Days 0, 45 and 90

  2. Plasma albumin level (g/l)

    blood sample.

    Time frame: Days 0, 45 and 90

  3. Frailty screening tool

    Determination of fragility status. 3 status : Dependent, Fragile, Robust

    Time frame: Days 0 and 90

  4. Mini Nutritional Assessment score

    Determine nutritional status. Score : 0-30

    Time frame: Days 0 and 90

  5. Inflammatory status

    Analysis of inflammatory status by blood sample results. C-reactive protein (CRP), Interleukin 6 (IL-6), Tumor necrosis factor (TNFα), monocyte chemoattractant protein 1 (MCP1)

    Time frame: Days 0, 45 and 90

  6. Hand Grip test (N)

    Analysis of muscle function tests.

    Time frame: Days 0 and 90

  7. 6 minutes walk test (m)

    Analysis of muscle function tests.

    Time frame: Days 0 and 90

  8. Maximal voluntary contraction of quadriceps (N)

    Analysis of muscle function tests.

    Time frame: Days 0 and 90

  9. Get up-and-go test (s)

    Analysis of muscle function tests.

    Time frame: Days 0 and 90

  10. Profiles of the differential expression of potentials biomarkers

    Analysis of profiles of the differential expression of potentials biomarkers by results of blood sample with heparin, urine sample and white blood cells.

    Time frame: Days 0, 45 and 90

  11. microbiota

    Analysis of microbiota by stool sample results.

    Time frame: Days 0 and 90

07

Study locations

3 sites
  • EHPAD Cité des Aînés
    Saint-Étienne, France
  • EHPAD La Cerisaie
    Saint-Étienne, France
  • EHPAD Le Soleil
    Saint-Étienne, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03867006
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Bioparhom, France, Regional Council of Auvergne-Rhône-Alpes
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
Feb 8, 2019
Primary completion
Oct 31, 2022
Completion
Oct 31, 2022
Last update
Apr 18, 2023

Study contacts

Sergio POLAKOF, PhD
study director · UMR 1019, INRA, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion